No title
FLT3 is a critical prognostic marker in acute myeloid leukemia (AML) due to its high frequency of mutation. Primary mutations in FLT3 include point mutations or deletions in the tyrosine kinase domain (TKD) and internal tandem duplications (ITD) in the juxtamembrane (JM) region. These mutations lead to ligand-independent activation, disrupting the JM region and kinase domain interaction, resulting
